Bartlett was The Temper Trap Director of the Surgical Intensive

Bartlett was reports disposition by the temper trap Director of temper trap conclude the Surgical Intensive Care Unit,Chief of the Trauma/Critical Care division and Director of theExtracorporeal Life Support Program at UMHS Among Dr. Bartlett's manydistinguished accomplishments, he is best known as the pioneer in thedevelopment of the extracorporeal membrane oxygenation machine (ECMO),used to oxygenate blood in critically ill patients worldwide. He receivedhis MD from the University of Michigan Medical School, cum laude,completed his general surgery residency at Peter Bent Brigham Hospital inBoston, and was Chief Resident in thoracic surgery. He was alsopreviously faculty at the University of California, Irvine Dr.

Bartlettis the recipient of 26 separate research grants, 14 from the NationalInstitutes of Health, including an RO1 grant for the development of acompletely artificial lung disposition the temper trap . He has also received numerous national andinternational awards for his contributions to critical care medicine."We are truly fortunate to have Dr the pretenders tour . Bartlett join the Company as ChiefMedical Officer," stated Dr Chan "Dr temper trap wiki . Bartlett is well-respected in thecritical care community and brings a wealth of experience to MedaSorb andCytoSorbents, including the treatment of sepsis, acute respiratorydistress syndrome, the use of extracorporeal therapies, and clinicaltrials Dr temper trap .

Bartlett provides the exact expertise the Company needs atthis juncture and we are excited to work with him more closely."About MedaSorb, CytoSorbents and CytoSorb(TM)MedaSorb Technologies Corporation with its wholly-owned operatingsubsidiary, CytoSorbents, Inc., is a medical device company focused on thetreatment of sepsis with its proprietary CytoSorb(TM) resin science of fear the temper trap . Sepsis, oftencalled "overwhelming infection," afflicts more than 2 million peopleworldwide each year, killing one in every three patients, despite the bestmedical treatment the pretenders tour . CytoSorb(TM) is designed to treat sepsis by broadlyremoving toxins from blood that cause organ failure and potentially death.The Company is currently evaluating CytoSorb(TM) in its 60-patientEuropean sepsis trial.Forward-Looking StatementsThis press release includes forward-looking statements intended to qualifyfor the safe harbor from liability established by the Private SecuritiesLitigation Reform Act of 1995 temper trap wiki . Forward-looking statements in this pressrelease are not promises or guarantees and are subject to risks anduncertainties that could cause our actual results to differ materiallyfrom those anticipated temper trap . These statements are based on management's currentexpectations and assumptions and are naturally subject to uncertainty andchanges in circumstances.

We caution you not to place undue reliance uponany such forward-looking statements . Actual results may differ materiallyfrom those expressed or implied by the statements herein the pretenders tour . MedaSorbTechnologies Corporation believes that its primary risk factors include,but are not limited to: obtaining government approvals including requiredFDA approvals; ability to successfully develop commercial operations;dependence on key personnel; acceptance of the Company's medical devicesin the marketplace; the outcome of pending and potential litigation;compliance with governmental regulations; reliance on research and testingfacilities of various universities and institutions; the ability to obtainadequate financing in the future when needed; product liability risks;limited manufacturing experience; limited marketing, sales anddistribution experience; market acceptance of the Company's products;competition; unexpected changes in technologies and technologicaladvances; and other factors detailed in the Company's Form 10-KSB filedwith the SEC on April 15, 2008, which is available at Technologies CorporationDavid Lamadrid(732) 329-8885 ext temper trap wiki . Copyright 2009, Market Wire, All rights reserved.-0- . If any one saw the pheonix race yesterday 10/15/2009, you saw what a disaster it was for Dale jr. it began innocently enough the race was going good  for  him he appeared to be moving up.